Z79.69 is a billable ICD-10 code used to specify a medical diagnosis of long term (current) use of other immunomodulators and immunosuppressants. The code is valid during the fiscal year 2023 from October 01, 2022 through September 30, 2023 for the submission of HIPAA-covered transactions. The code is exempt from present on admission (POA) reporting for inpatient admissions to general acute care hospitals.
This code describes a circumstance which influences the patient's health status but not a current illness or injury. The code is unacceptable as a principal diagnosis.
The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:
- Long term current use of adalimumab therapy
- Long-term current use of certolizumab pegol
- Long-term current use of etanercept
- Long-term current use of leflunomide
New 2023 ICD-10 Code
Z79.69 is new to ICD-10 code set for the FY 2023, effective October 1, 2022. The National Center for Health Statistics (NCHS) has published an update to the ICD-10-CM diagnosis codes which became effective October 1, 2022. This is a new and revised code for the FY 2023 (October 1, 2022 - September 30, 2023).
Index to Diseases and Injuries References
The Index to Diseases and Injuries is an alphabetical listing of medical terms, with each term mapped to one or more ICD-10 code(s). The following references for this diagnosis code are found in the injuries and diseases index:
The Medicare Code Editor (MCE) detects and reports errors in the coding of claims data. The following ICD-10 Code Edits are applicable to this code:
Present on Admission (POA)
Z7969 replaces the following previously assigned ICD-10 code(s):
- FY 2023 - Code Added, effective from 10/1/2022 through 9/30/2023